Oral Mucosa Wound Healing After Gingival Recession Treatment in Diabetic Patients

This study is looking at how well oral wounds heal after a dental procedure called Coronally Advance Flap associated with connective tissue graft (CAF+CTG) in people with diabetes compared to those without diabetes. CAF+CTG is a surgical procedure to treat gum recession (when the gum pulls away from the tooth). Researchers want to see if the amount of gum recession reduction is different between these two groups. They also want to understand if factors like the oral microbiome (the germs in your mouth) and inflammation play a role in healing. You might be able to join if you are 18 or older, have gum recession, and either have diabetes (HbA1c >7%) or do not have diabetes. The main goal is to measure how much the gum recession is reduced after 6 months.

Study design: This is an interventional study with a planned enrollment of 40 participants. It compares healing in diabetic and non-diabetic individuals.
What's involved: Participants will receive the CAF+CTG procedure to treat their gum recession. You will also need to attend follow-up visits at 7, 14, 30, 90, and 180 days after the treatment.
Compensation: Not stated in the trial record.
Follow-up: Participants will be followed for 6 months after treatment to measure gingival recession reduction.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Oral Mucosa Wound Healing After Gingival Recession Treatment in Diabetic Patients. A Clinical Study.

Not Yet Recruiting

NAAges 18+InterventionalTreatment

Mauro Santamaria

~40 participants

Updated 2026-08-24 on ClinicalTrials.gov

What's tested:Coronally Advance Flap associated with connective tissue graft (CAF+CTG)

At a glance

Recruiting sites

0 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

gingival recession reduction

Measured over 6 months

Conditions

Diabetes Mellitus

Gingival Recession, Generalized

Gingival Recession, Localized

Where it's being run

1 sites across 1 states

Kentucky1

Study leadership

Mauro Santamaria, DDS, MS, PhD · PRINCIPAL_INVESTIGATOR · University of Kentucky

Who to contact

Dawn G Dawson

[email protected]

8593235409

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

aged ≥ 18 years;

non-diabetic and diabetic patients (HbA1c\>7% (American Diabetes Association 2025) managed with oral hypoglycemic agents or insulin;

in the need of gingival recession treatment (RT1) in upper or lower arches with identifiable or restored cement-enamel junction (CEJ);

periodontal stable (BoP ≤25%)(Lang et al. 2003);

no morphological or pathological conditions in the palatal mucosa.

Exclusion

patients with cardiovascular, blood dyscrasias, and immunodeficiency that contraindicate surgical procedures;

taking medications known to interfere with the wound healing process or that contraindicate the surgical procedure;

Pregnancy/lactation (assessed via self-report);

current opportunistic oral lesions that mainly colonize the palate region;

subjects that have taken antibiotics within the last 3 months or need for antibiotic prophylaxis;

prisoners;

signs or symptoms of active extra-oral head and neck infection (swelling) as determined by a dentist at the time of evaluation;

subjects who cannot read or speak English or Spanish, and do not agree to having the assistance of an interpreter

What this trial measures

gingival recession reduction6 months
The amount of reduction in the gingival recession defect. It is calculated by subtracting the final gingival recession values from the initial values

Trialytics